Dr. Reddy's Laboratories Limited is a globally integrated pharmaceutical company. The company is headquartered in Hyderabad, India.
| Revenue (TTM) | $331.19B |
| Gross Profit (TTM) | $166.18B |
| EBITDA | $54.67B |
| Operating Margin | 4.25% |
| Return on Equity | 8.84% |
| Return on Assets | 4.01% |
| Revenue/Share (TTM) | $66.41 |
| Book Value | $0.81 |
| Price-to-Book | 2.58 |
| Price-to-Sales (TTM) | 0.03 |
| EV/Revenue | 3.015 |
| EV/EBITDA | 14.98 |
| Quarterly Earnings Growth (YoY) | -68.70% |
| Quarterly Revenue Growth (YoY) | -5.60% |
| Shares Outstanding | $832.99M |
| Float | $3.59B |
| % Insiders | 0.00% |
| % Institutions | 15.90% |
Volatility is currently expanding
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited (“Dr. Reddy's” or the “Company”) (NYSE: RDY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Dr Reddy's Laboratories said on Friday it signed a deal with Takeda Pharmaceutical Company for the promotion and distribution of the Qdenga dengue vaccine in India.
NEW YORK, Sept. 17, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE: RDY).
NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited (“Dr. Reddy's” or the “Company”) (NYSE: RDY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited (“Dr. Reddy's” or the “Company”) (NYSE: RDY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Sept. 3, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE: RDY).
NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited (“Dr. Reddy's” or the “Company”) (NYSE: RDY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE: RDY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)---- $RDY #Bridion--Dr. Reddy's Laboratories today announced launch of Sugammadex Injection of Single-Dose Vials, a generic equivalent of Bridion®, in the United States.
Investigation focuses on RDY losses after Dr. Reddy's disclosed a ₹2.4 billion provision tied to out-of-spec semaglutide batches and shares fell approximately 9%. NEW YORK, July 31, 2026 /PRNewswire/ -- On July 22, 2026, Dr. Reddy's Laboratories (NYSE: RDY) shares fell approximately 9% after the Company reported a Q1 FY27 earnings miss and disclosed a ₹2.4 billion provision tied to out-of-spec semaglutide batches.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on RDY and any ticker you trade — then tracks every position and per-strategy win rate.
